Boehringer Ingelheim To Present Data At RAS Summit Europe

Last week marked an exciting time for the RAS community with Boehringer Ingelheim advancing the first Pan-KRAS inhibitor into clinical testing.

Don’t miss this unique opportunity to hear from Darryl McConnell, Senior Vice President at Boehringer Ingelheim first-hand at RAS- Targeted Drug Discovery Europe on different approaches to drugging KRAS beyond G12C with small molecules.

What else will be discussed at the meeting?

We’ve got 23 world-class speakers re-defining the undruggable nature of RAS proteins, including:

• Julian Downward, Associate Research Director, Francis Crick Institute
• Dwight Nissley, Director, NCI RAS Initiative, Frederick National Laboratory for Cancer Research
• Laurent Debussche, Vice President, Global Head – Molecular Oncology, Sanofi
• Steve Kelsey, President, Research & Development, Revolution Medicines
• Stig Hansen, Chief Executive Officer, Carmot Therapeutics
• Grahame Mckenzie, Chief Scientific Officer, PhoreMost
• Juan Perez, Chief Science Officer, Allinky Biopharma
• Sreesha Srinivasa, Senior Vice President, Oblique Therapeutics

Be part of the only translational and European-centric meeting designed to help drug developers finally drug the “undruggable” RAS family of proteins. Advance novel target site discovery, improve drug-like properties and accelerate the translation of robust therapeutic strategies to finally target RAS mutants successfully. Download the full event guide to learn more: https://ter.li/5q78sm

Register quoting VIP Code 16119PJPRS to save 10% off your ticket. Visit the website to see all pricing information, discounts and early booking deadlines: https://ter.li/l9n1xr